Ambu A/ S stock (DK0060946788): Q2 organic growth, guidance tweak and US?listed OTC shares gap down on earnings miss

Ambu A/S posted Q2 organic revenue growth of 7.3% and updated its full?year outlook, while its OTC?listed shares in the US gapped down after missing EPS estimates.

Ambu A/S reported its second?quarter and first?half results for fiscal 2025/26, showing 7.3% organic revenue growth and a solid EBIT margin, even as the company slightly narrowed its full?year growth guidance and its US?listed OTC shares reacted with a gap?down move after missing earnings per share estimates.

For Q2 2025/26, Ambu delivered organic revenue growth of 7.3%, driven by continued strong performance in its market?leading Endoscopy Solutions business, which grew 13.8% organically, while the Anesthesia & Patient Monitoring (A&PM) segment declined by 2.5% year?on?year, according to an interim report published via Via Ritzau on May 6, 2026 Via Ritzau as of 05/06/2026. Reported EBIT (before special items) was DKK 173 million, corresponding to an EBIT margin of 11.0%, reflecting stable profitability despite the mixed segment performance.

For the full fiscal year 2025/26, Ambu now expects organic revenue growth of 10–12%, slightly below the previous 10–13% range, with the adjustment driven by the year?to?date decline in A&PM, which the company now expects to grow in the low?single?digit range for the year instead of mid?single?digits Via Ritzau as of 05/06/2026. The EBIT margin guidance of 12–14% remains unchanged, signaling management’s confidence in maintaining profitability while executing its ZOOM AHEAD strategy and advancing toward global endoscopy leadership.

On the US?listed front, Ambu A/S (OTCMKTS:AMBBY) reported quarterly earnings results on Wednesday, May 6, 2026, with earnings per share of $0.07 for the quarter, according to a MarketBeat earnings alert MarketBeat as of 05/06/2026. The company also posted a net margin of 8.86% and a return on equity of 9.15% for the period, highlighting ongoing profitability in its single?use medical device business.

Following the earnings release, Ambu’s OTC?listed shares in the United States gapped down, reflecting investor disappointment that statutory earnings missed analyst expectations by about 13%, even though revenue came in only slightly below consensus at around DKK 1.6 billion, according to a Simply Wall St analysis of the latest quarterly report Simply Wall St as of 05/06/2026. The move underscores the sensitivity of the US?listed OTC shares to earnings surprises despite the company’s underlying organic growth.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ambu A/S
• Sector/industry: Medical devices, single?use diagnostics and life?supporting equipment
• Headquarters/country: Denmark
• Core markets: Hospitals, clinics, emergency and rescue services globally
• Key revenue drivers: Endoscopy Solutions (including disposable endoscopes), Anesthesia & Patient Monitoring, respiratory and airway management products
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: AMBU B); also listed in the US via OTC (ticker: AMBBY)
• Trading currency: DKK on Nasdaq Copenhagen; USD on OTC

Ambu A/S: core business model

Ambu A/S is a Denmark?based medical device company that focuses on single?use diagnostic and life?supporting equipment for hospitals, clinics, and emergency and rescue services, according to MarketBeat’s earnings alert MarketBeat as of 05/06/2026. The company’s business model centers on providing disposable medical devices that help reduce the risk of cross?contamination and streamline clinical workflows, particularly in endoscopy, anesthesia, and airway management.

Ambu’s products are designed to support procedures such as endoscopic examinations, airway intubation, and patient monitoring during anesthesia, with an emphasis on single?use solutions that can be safely discarded after each patient, according to TradingView’s overview of Ambu’s financials TradingView as of 05/06/2026. This focus on disposables differentiates Ambu from traditional reusable device manufacturers and aligns with growing regulatory and clinical pressure to minimize infection risks in healthcare settings.

The company’s strategy, branded as ZOOM AHEAD, aims to strengthen its position in endoscopy and respiratory care while maintaining profitability through disciplined cost management and innovation in single?use technologies, as highlighted in the Q2 2025/26 interim report Via Ritzau as of 05/06/2026. This strategy underpins Ambu’s efforts to achieve global leadership in endoscopy and to expand its footprint in respiratory and airway management markets.

Main revenue and product drivers for Ambu A/S

Ambu’s revenue is primarily driven by its Endoscopy Solutions business, which includes disposable endoscopes and related accessories used in gastrointestinal and other endoscopic procedures, according to Marketscreener’s company profile Marketscreener as of 05/06/2026. In Q2 2025/26, Endoscopy Solutions grew 13.8% organically, contributing significantly to the group’s 7.3% organic revenue growth and reinforcing its role as the main growth engine.

The Anesthesia & Patient Monitoring (A&PM) segment, which supplies disposable airway management and monitoring products for anesthesia procedures, has faced softer demand, with a 2.5% organic decline in Q2 2025/26 and a year?to?date performance that led management to lower its full?year growth expectation for this segment to low?single?digits Via Ritzau as of 05/06/2026. Despite this headwind, A&PM remains a core part of Ambu’s portfolio, providing recurring revenue from consumables used in routine anesthesia workflows.

Respiratory and airway management products, including tools such as SureSight™ that assist clinicians in managing airway intubation, are also emerging as important growth drivers, with increasing momentum reported in the Q2 2025/26 update Via Ritzau as of 05/06/2026. These products benefit from rising awareness of airway safety and the need for reliable, single?use solutions in emergency and critical?care settings, positioning Ambu to capture additional share in respiratory care markets.

Why Ambu A/S matters for US investors

For US investors, Ambu A/S offers exposure to the global single?use medical device market through its OTC?listed shares (ticker: AMBBY), which trade in USD and provide access to a Danish company with a strong presence in endoscopy and anesthesia markets MarketBeat as of 05/06/2026. The US healthcare system, with its high demand for infection?control solutions and advanced endoscopic procedures, represents a key growth region for Ambu’s products, particularly in hospitals and ambulatory surgery centers.

The company’s focus on single?use endoscopes and airway management tools aligns with US regulatory trends and hospital protocols that increasingly favor disposable devices to reduce the risk of device?related infections and simplify reprocessing workflows TradingView as of 05/06/2026. This regulatory and clinical tailwind supports long?term demand for Ambu’s portfolio, even as near?term earnings volatility can affect the OTC?listed shares.

US investors also benefit from Ambu’s diversified geographic footprint, with sales across North America, Europe, and Asia?Pacific, which helps mitigate regional demand fluctuations and provides multiple avenues for growth Marketscreener as of 05/06/2026. The combination of organic growth in endoscopy, ongoing innovation in respiratory products, and a stable EBIT margin outlook makes Ambu an interesting name for investors seeking exposure to the medical device sector with a focus on single?use technologies.

Conclusion

Ambu A/S delivered solid organic revenue growth of 7.3% in Q2 2025/26, led by strong performance in its Endoscopy Solutions business, while the Anesthesia & Patient Monitoring segment weighed on the group’s overall growth trajectory Via Ritzau as of 05/06/2026. The company maintained its EBIT margin guidance of 12–14% for the full year, signaling confidence in profitability despite a slightly narrower revenue outlook.

For US investors, Ambu’s OTC?listed shares provide access to a Denmark?based medical device company with a leading position in single?use endoscopy and airway management products, operating in a global market that continues to favor disposable solutions for infection control MarketBeat as of 05/06/2026. However, the recent earnings miss and share price reaction highlight the volatility that can accompany earnings releases, underscoring the importance of understanding both the company’s growth drivers and the risks associated with its segment mix and global demand trends.

Investors considering Ambu A/S should weigh the company’s organic growth potential in endoscopy and respiratory care against the near?term headwinds in anesthesia and patient monitoring, as well as the broader macroeconomic and regulatory environment for medical devices Marketscreener as of 05/06/2026. As with any stock, Ambu A/S should be evaluated within a diversified portfolio and in line with individual risk tolerance and investment objectives.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.